Abstract The use of medical Cannabis has increased in recent years due to changing legal circumstances in many countries. Approval exists only for a few neurological conditions such as rare forms of…
Condition: Epilepsy
Cannabis use patterns in drug-resistant and pharmacoresponsive epilepsy: Single tertiary referral center survey investigation
Abstract This study sought to identify differences in cannabis use and perceptions about cannabis in mitigating seizure-related symptoms in patients with epilepsy, and to evaluate differences in these patterns between…
Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome
Please use this link to access this publication: https://www.epilepsybehavior.com/article/S1525-5050(15)00157-2/fulltext Abstract There is a great need for safe and effective therapies for treatment of infantile spasms (IS) and Lennox-Gastaut syndrome (LGS). Based…
Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome A Randomized Clinical Trial
Key Points Question Is adjunctive cannabidiol at doses of 10 and 20 mg/kg/d superior to placebo in reducing convulsive seizure frequency in patients with Dravet syndrome? Findings This double-blind clinical trial randomized…
Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study
Abstract The objective of this study was to characterize the changes in adverse events, seizure severity, and frequency in response to a pharmaceutical formulation of highly purified cannabidiol (CBD; Epidiolex®)…
Quality of life in adults enrolled in an open-label study of cannabidiol (CBD) for treatment-resistant epilepsy
Please follow this link to access this publication: https://www.sciencedirect.com/science/article/abs/pii/S1525505019301167 Abstract Treatment-resistant epilepsy (TRE) is associated with low quality of life (QOL). Cannabidiol (CBD) may improve QOL, but it is unclear…
Are there mortality risks for patients with epilepsy who use cannabis treatments as monotherapy?
Abstract Mortality associated with cannabis used for treatment of epilepsy is not well documented. We discuss two fatalities in the setting of epilepsy and self-determined therapy with cannabis (SDTC). One…
Cannabidiol for Treatment of Childhood Epilepsy–A Cross-Sectional Survey
Abstract Background: The interest in cannabidiol (CBD) for treatment of epilepsy has been increasing over the last years. However, practitioner’s attitudes concerning the use of CBD for epilepsy treatment appears to…
Marijuana use among patients with epilepsy at a tertiary care center
Abstract The expansion of medical and recreational marijuana legalization facilitates patient access to cannabis, and many patients with epilepsy pursue marijuana as a treatment for seizures. We administered a nine-item…
Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders
Please follow this link to access the full article: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(19)30032-8/fulltext Abstract In the past two decades, there has been an increasing interest in the therapeutic potential of cannabinoids for neurological disorders…